Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction

Senthil Selvaraj, Brian Claggett, Sanjiv J. Shah, Inder Anand, Jean L. Rouleau, Eileen O'Meara, Akshay S. Desai, Eldrin F. Lewis, Bertram Pitt, Nancy K Sweitzer, James C. Fang, Marc A. Pfeffer, Scott D. Solomon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13% had macroalbuminuria, and 80% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95% CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95% CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39% in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95% CI, 0.49-0.77) and by 76% (geometric mean ratio, 0.24; 95% CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50% was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.

Original languageEnglish (US)
Pages (from-to)e005288
JournalCirculation. Heart failure
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Spironolactone
Albuminuria
Heart Failure
Albumins
Creatinine
Blood Pressure
Hospitalization
Placebos
Mineralocorticoid Receptor Antagonists
Mortality
Angiotensin Receptor Antagonists
Heart Arrest
Angiotensin-Converting Enzyme Inhibitors
Diabetes Mellitus
Clinical Trials
Hypertension
Kidney
Safety
Therapeutics

Keywords

  • albuminuria
  • blood pressure
  • diabetes mellitus
  • heart failure
  • kidney
  • spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Selvaraj, S., Claggett, B., Shah, S. J., Anand, I., Rouleau, J. L., O'Meara, E., ... Solomon, S. D. (2018). Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation. Heart failure, 11(11), e005288. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005288

Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. / Selvaraj, Senthil; Claggett, Brian; Shah, Sanjiv J.; Anand, Inder; Rouleau, Jean L.; O'Meara, Eileen; Desai, Akshay S.; Lewis, Eldrin F.; Pitt, Bertram; Sweitzer, Nancy K; Fang, James C.; Pfeffer, Marc A.; Solomon, Scott D.

In: Circulation. Heart failure, Vol. 11, No. 11, 01.11.2018, p. e005288.

Research output: Contribution to journalArticle

Selvaraj, S, Claggett, B, Shah, SJ, Anand, I, Rouleau, JL, O'Meara, E, Desai, AS, Lewis, EF, Pitt, B, Sweitzer, NK, Fang, JC, Pfeffer, MA & Solomon, SD 2018, 'Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction', Circulation. Heart failure, vol. 11, no. 11, pp. e005288. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005288
Selvaraj, Senthil ; Claggett, Brian ; Shah, Sanjiv J. ; Anand, Inder ; Rouleau, Jean L. ; O'Meara, Eileen ; Desai, Akshay S. ; Lewis, Eldrin F. ; Pitt, Bertram ; Sweitzer, Nancy K ; Fang, James C. ; Pfeffer, Marc A. ; Solomon, Scott D. / Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. In: Circulation. Heart failure. 2018 ; Vol. 11, No. 11. pp. e005288.
@article{70b5c0964823432fa17240036e2cf563,
title = "Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction",
abstract = "BACKGROUND: Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13{\%} had macroalbuminuria, and 80{\%} were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95{\%} CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95{\%} CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39{\%} in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95{\%} CI, 0.49-0.77) and by 76{\%} (geometric mean ratio, 0.24; 95{\%} CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50{\%} was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.",
keywords = "albuminuria, blood pressure, diabetes mellitus, heart failure, kidney, spironolactone",
author = "Senthil Selvaraj and Brian Claggett and Shah, {Sanjiv J.} and Inder Anand and Rouleau, {Jean L.} and Eileen O'Meara and Desai, {Akshay S.} and Lewis, {Eldrin F.} and Bertram Pitt and Sweitzer, {Nancy K} and Fang, {James C.} and Pfeffer, {Marc A.} and Solomon, {Scott D.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.118.005288",
language = "English (US)",
volume = "11",
pages = "e005288",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction

AU - Selvaraj, Senthil

AU - Claggett, Brian

AU - Shah, Sanjiv J.

AU - Anand, Inder

AU - Rouleau, Jean L.

AU - O'Meara, Eileen

AU - Desai, Akshay S.

AU - Lewis, Eldrin F.

AU - Pitt, Bertram

AU - Sweitzer, Nancy K

AU - Fang, James C.

AU - Pfeffer, Marc A.

AU - Solomon, Scott D.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - BACKGROUND: Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13% had macroalbuminuria, and 80% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95% CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95% CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39% in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95% CI, 0.49-0.77) and by 76% (geometric mean ratio, 0.24; 95% CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50% was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.

AB - BACKGROUND: Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13% had macroalbuminuria, and 80% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95% CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95% CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39% in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95% CI, 0.49-0.77) and by 76% (geometric mean ratio, 0.24; 95% CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50% was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.

KW - albuminuria

KW - blood pressure

KW - diabetes mellitus

KW - heart failure

KW - kidney

KW - spironolactone

UR - http://www.scopus.com/inward/record.url?scp=85058907808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058907808&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.118.005288

DO - 10.1161/CIRCHEARTFAILURE.118.005288

M3 - Article

C2 - 30571191

AN - SCOPUS:85058907808

VL - 11

SP - e005288

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 11

ER -